| Metric | Value (₹ Cr) | vs Q3 FY26 |
|---|---|---|
| Revenue | 244.61 | 24.3% |
| Total Income | 244.93 | 24.3% |
| Expenditure | 222.33 | 25.7% |
| PBT | 22.60 | 29.8% |
| Net Profit | 16.54 | 24.8% |
| OPM | 13.29% | 4.65pp |
| NPM | 6.75% | 2.65pp |
| EPS | 1.63 | 28.4% |
Regaal Resources FY26 PAT Up 16.6% YoY to ₹556 Million
27 May 2026 · 27 May, 9:32 pm
Summary
Regaal Resources Limited reported robust financial results for Q4 FY26 and the full financial year 2026. For Q4 FY26, Profit After Tax witnessed a substantial 47.9% year-on-year increase, reaching ₹165 million, with PAT margins improving to 6.8%. The full year FY26 saw Operating Income grow by 23.9% year-on-year to ₹11,342 million, while PAT increased by 16.6% to ₹556 million, achieving a margin of 4.9%. Management noted that the improvement in Q4 FY26 Operating EBITDA margin was primarily driven by lower trading activity and better realizations from the core product portfolio. The company also announced significant strategic expansions, including doubling its maize crushing capacity and commissioning new manufacturing facilities, establishing itself as the largest maize wet milling facility in Eastern India, with further value-added product expansions slated for FY27.
Key Highlights
- 1
Profit After Tax (PAT) for Q4 FY26 surged by 47.9% year-on-year to ₹165 million, with PAT margins strengthening to 6.8%.
- 2
For the full financial year 2026, Operating Income (revenue) grew significantly by 23.9% year-on-year, reaching ₹11,342 million.
- 3
Full-year PAT for FY26 stood at ₹556 million, reflecting a solid growth of 16.6% year-on-year, with PAT margins at 4.9%.
- 4
The Board of Directors has recommended a dividend of ₹0.25 per share for FY26, pending shareholders' approval.
- 5
Regaal Resources successfully doubled its maize crushing capacity from 825 MT per day to 1,650 MT per day on May 26, 2026.
- 6
The company commissioned new Liquid Glucose (180 MT/day) and Maltodextrin Powder (50 MT/day) manufacturing facilities, coupled with an expansion of its captive co-generation power plant to 15.8 MW.
- 7
Further expansion into high value-added modified starch products, including Dextrose Anhydrous, Monohydrate, and Hydrol, is underway, with commissioning anticipated over the course of FY27.
Management Comments
Anil Kishorepuria
We are pleased to present Regaal's performance for FY26. For the full year, our Operating Income stood at ₹ 11,342 million, reflecting a growth of 23.9% year-on-year, while Value-Add stood at ₹ 2,958 million, a growth of 18.0% year-on-year. Operating EBITDA for FY26 stood at ₹ 1,266 million, registering a YoY growth of 12.2%, with a margin of 11.2%, while PAT for FY26 stood at ₹ 556 million, reflecting a growth of 16.6% YoY, with a margin of 4.9%. For Q4 FY26, Operating Income stood at ₹ 2,446 million, Value-Add at ₹ 749 million, and Operating EBITDA at ₹325 million with a margin of 13.3%. The improvement in the Operating EBITDA margin was primarily driven by lower trading activity during the quarter and better realizations across the Company’s core product portfolio. The Board has recommended a dividend of ₹ 0.25 per share for FY26, subject to shareholders’ approval. On 26th May 2026, we successfully doubled our crushing capacity from 825 MT per day to 1,650 MT per day. We also commissioned a new Liquid Glucose ("LG") manufacturing facility with a production capacity of 180 MT per day and a new Maltodextrin Powder (“MDP”) manufacturing facility with a production capacity of 50 MT per day. These developments, along with the expansion of our captive co-generation power plant from 7.1 MW to 15.8 MW make Regaal the largest maize wet milling facility in Eastern India. This marks a defining milestone in our journey towards becoming a diversified maize-based specialty products company, strengthening our presence in higher value-added products across the food, pharmaceutical, agriculture, and healthcare sectors. We are also undertaking further expansion of our value-added product segment with a range of modified starch products and derivatives including Dextrose Anhydrous, Dextrose Monohydrate, and Hydrol, for which the associated capex is already underway, and commissioning is expected over the course of FY27. We remain focused on optimizing our expanded operations while maintaining strong capital discipline and a commitment to sustainable business practices to ensure long-term value creation for all our stakeholders.
Informational and educational content only. Not investment advice.